Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Article | IMSEAR | ID: sea-199600

ABSTRACT

Background: Aloe vera (Family Liliaceae) has been used for the treatment of diabetes, skin disorders and as anti-inflammatory agent. Objectives: behavioral testing of antiparkinsonian effect of Aloe vera in MPTP induced animal model.Methods: Rotarod test and Catalepsy bar test were used for behavioral assessment. Assessment of oxidative stress was done in the striatal region of the brain by reduced glutathione (GSH) measurement.Results: A. vera (200 and 400mg/kg, p.o.) was found to significantly increase the retention time in rota rod test and significantly decrease the latency period in catalepsy bar test as compared to MPTP groups. A. vera was found to have significant anti-oxidative effect in the striatal region of the brain by GSH measurement.Conclusions: Thus, it can be proposed that A. vera has a potential anti-parkinson effect in mice.

2.
Article in English | IMSEAR | ID: sea-165060

ABSTRACT

Background: The objectives of the present study were to compare the effect of lignocaine (1.5 mg/kg IV given 3 mins before laryngoscopy and intubation), esmolol (300 μg/kg as a bolus 2 mins before intubation), and dexmedetomidine (0.5 μg/kg IV over 10 mins) on the pressor response in non-hypertensive American Society of Anesthesiologists (ASA) Grade I and II patients posted for elective surgery and the pharmacoeconomic and pharmacoepidemiological inferences drawn on comparison of these drugs. Methods: After approval by the Institutional Ethics Committee, 90 consenting adult patients aged 18-65 years of age of either sex of non-hypertensive ASA Grade I or II undergoing elective surgery under general anesthesia with endotracheal intubation were included in this randomized, prospective study protocol. (1) Group L: Patients were given IV lignocaine 1.5 mg/kg. (2) Group E: Patients were given IV esmolol 300 μg/kg. (3) Group D: Patients were given IV dexmedetomidine 0.5 μg/kg. Adequate monitoring, oxygenation, and hydration were established on the entry in the operating room (OR). All hemodynamic data were measured on arrival in OR, before induction, before intubation, and at 1, 3, 5 mins after intubation by an independent observer. Anesthesia was induced with thiopental sodium and fentanyl 2 μg/kg; intubation was performed with cuffed oral endotracheal tube of appropriate size for airway management. Surgery was allowed to start only after 5 mins of intubation. Results: Esmolol effectively blunted the blood pressure response to intubation, but incompletely attenuated the increase in heart rate (HR). Dexmedetomidine was more effective than lignocaine in minimizing the increase in HR, systolic blood pressure (SBP), and diastolic blood pressure (DBP) subsequent to endotracheal intubation. Conclusion: Dexmedetomidine 0.5 μg/kg has manifested to maintain hemodynamic stability associated with intubation and hence may prove benefi cial for cardiac patients where the stress response to laryngoscopy and intubation is highly undesirable.

SELECTION OF CITATIONS
SEARCH DETAIL